| Dr Charles Jared Randall, DDS | |
|
3285 E. 17th St., Ammon, ID 83406-6758 | |
| (208) 523-3380 | |
| (208) 523-3077 |
| Full Name | Dr Charles Jared Randall |
|---|---|
| Gender | Male |
| Speciality | Dentist - Orthodontics And Dentofacial Orthopedics |
| Location | 3285 E. 17th St., Ammon, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710035829 | NPI | - | NPPES |
| 806122100 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223X0400X | Dentist - Orthodontics And Dentofacial Orthopedics | D-3405-OR (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles Jared Randall, DDS 3285 E. 17th St., Ammon, ID 83406-6758 Ph: (208) 523-3380 | Dr Charles Jared Randall, DDS 3285 E. 17th St., Ammon, ID 83406-6758 Ph: (208) 523-3380 |
News Archive
Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company's lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.
Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.
Boston Scientific Corporation today announced that it has received U.S. Food and Drug Administration clearance for the two validated manufacturing changes affecting all of its cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators, and that it will immediately resume distribution of its COGNIS CRT-Ds and TELIGEN ICDs.
Ben Quirk and Quirk Healthcare donated over 800 hours of customization work to the Children's Diagnostic & Treatment Center's new Electronic Health Records system that launched on Monday, April 7, 2014.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has received approval by the U.S. Food and Drug Administration (FDA) to market the therascreen EGFR test as a companion diagnostic to guide the use of Boehringer Ingelheim's new targeted therapy, GILOTRIF™ (afatinib), for treatment of metastatic NSCLC in patients whose tumors have certain EGFR gene mutations.
› Verified 9 days ago
Monika M Attia, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2641 S 25th E, Ammon, ID 83406 Phone: 208-497-0049 | |
Dr. Kory Bingham, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 3299 E 17th St, Ammon, ID 83406 Phone: 208-529-3007 Fax: 208-529-1525 | |
Dr. Jed Karl Zirker, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 1801 S Ammon Rd, Ammon, ID 83406 Phone: 208-528-7665 Fax: 208-522-9556 | |
Dr. Randall G. Smith, Dentist Medicare: Not Enrolled in Medicare Practice Location: 2805 Eagle Drive, Ammon, ID 83406 Phone: 208-542-1333 Fax: 208-552-7296 | |
Theodore James, DDS Dentist Medicare: Accepting Medicare Assignments Practice Location: 2677 E 17th St Ste 600, Ammon, ID 83406 Phone: 208-705-9652 | |
Mark Marlowe, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 2805 Eagle Dr, Ammon, ID 83406 Phone: 208-542-1333 Fax: 208-552-7296 |